方法：选取2012年1-6mo在我院行白内障手术患者65例65眼。部分患者手术结束时前房给予莫西沙星，另外一部分作为对照组未使用莫西沙星。对患者术前和术后logMAR最佳矫正视力、眼内压、角膜水肿、前房形态进行检查。

结果：共33例患者(男19，女14)使用了莫西沙星，平均年龄64.81±11.61(41～82)岁； 32例患者(男15，女17)没有使用，平均年龄65.43±11.10(42-81)岁。患者的年龄(P=0.827)和性别(P=0.396)无统计学差异。术前两组的最佳矫正视力均接近20/130。术后，莫西沙星组和对照组的最佳矫正视力分别为20/25和20/23(P=0.160)。术前莫西沙星组眼内压为14.93±2.77(11-21)mmHg，对照组为15.06±2.42(12-21)mmHg(P=0.850)。术后，两组眼内压均无统计学差异\〖莫西沙星组：14.06±2.31(10-19)mmHg； 对照组：14.03±2.36(10-19)mmHg(P=0.726)\〗。两组角膜水肿(P=0.623)与前房细胞发生率(P=0.726)均无统计学差异。

结论：白内障手术后给予莫西沙星预防眼内炎是安全而有效的。

METHODS:Sixty-five eyes of 65 patients underwent cataract surgery between January and June 2012. Some patients received intracameral moxifloxacin at the end of surgery, while others did not(controls). Pre- and postperative logarithm of the minimum angle of resolution(logMAR)best corrected visual acuity(BCVA), intraocular pressure(IOP), corneal edema, and anterior chamber(AC)status were examined.

RESULTS: Thirty-three patients(19 males, 14 females); average age, 64.81±11.61y(range: 41-82y)received moxifloxacin and 32 patients(15 males, 17 females); average age, 65.43±11.10y(range: 42-81y)did not. The differences in patient age(P=0.827)and sex(P=0.396)were insignificant. Preoperative BCVA was approximately 20/130 in both groups. After surgery, moxifloxacin and control patients had a BCVA of 20/25 and 20/23, respectively(P=0.160). Preoperative IOP was 14.93±2.77mmHg(range: 11-21mmHg)in moxifloxacin patients and 15.06±2.42mm Hg(range: 12-21mmHg)in controls(P=0.850). After surgery, IOP was not statistically different between two groups(moxifloxacin: 14.06±2.31(range: 10-19mmHg), controls: 14.03±2.36mmHg(range: 10-19mmHg), P=0.960). Slight differences in corneal edema(P=0.623)and anterior chamber cell(P=0.726)incidences between two groups were not statistically significant.

CONCLUSION: Intracameral moxifloxacin is safe and effective in preventing endophtalmitis after cataract surgery.